AF-45
AF-45 inhibits IRAK4 and IRAK1, with IC50s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC50s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models.
For research use only. We do not sell to patients.
- Formula: C22H25N3O3
- Molecular Weight:379.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
IRAK4 128 nM (IC50) |
IRAK1 1765 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| J774.A1 | IC50 |
1.54 μM
Compound: d5; AF-45
|
Antiinflammatory activity in LPS-induced mouse J774.A1 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity in LPS-induced mouse J774.A1 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 38913701] |
| J774.A1 | IC50 |
2.75 μM
Compound: d5; AF-45
|
Antiinflammatory activity in LPS-induced mouse J774.A1 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity in LPS-induced mouse J774.A1 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 38913701] |
| RAW264.7 | IC50 |
1.27 μM
Compound: d5; AF-45
|
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 38913701] |
| RAW264.7 | IC50 |
2.6 μM
Compound: d5; AF-45
|
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 38913701] |
| THP-1 | IC50 |
0.53 μM
Compound: d5; AF-45
|
Antiinflammatory activity in LPS-induced human THP-1 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity in LPS-induced human THP-1 cells assessed as inhibition of IL-6 release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 38913701] |
| THP-1 | IC50 |
0.6 μM
Compound: d5; AF-45
|
Antiinflammatory activity in LPS-induced human THP-1 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
Antiinflammatory activity in LPS-induced human THP-1 cells assessed as inhibition of TNF-alpha release pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA
|
[PMID: 38913701] |
Chemical Information
-
Molecular Weight 379.45
-
Formula C22H25N3O3
-
SMILES
COC1=CC2=C(N=CN=C2O[C@H]3CC[C@@H](N)CC3)C=C1OCC4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)